Journey Medical (DERM)
(Delayed Data from NSDQ)
$6.99 USD
-0.36 (-4.90%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DERM 6.99 -0.36(-4.90%)
Will DERM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Other News for DERM
DERM: B. Riley Securities Raises Price Target for Journey Medical | DERM Stock News
New Price Target for Journey Medical (DERM)
Journey Medical price target raised by $3 at B. Riley, here's why
DERM Expands Coverage for Rosacea Treatment Emrosi | DERM Stock News